A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome

Leukemia Research

Volumn 33, Issue 2, 2009, Pages 222-231

  Kim, Hawk ^a   Min, Young Joo ^a   Baek, Jin Ho ^a   Shin, Su Jin ^a   Lee, Eun Hee ^a   Noh, Eui Kyu ^a   Kim, Mee Young ^a   Park, Jae Hoo ^a  

^a Ulsan University College of Medicine   (South Korea)

Author keywords

Alemtuzumab; Bone marrow failure syndrome; Cyclosporine

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CYCLOSPORIN;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; APLASTIC ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW DEPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FEVER; DRUG WITHDRAWAL; FEMALE; GINGIVA HYPERTROPHY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MYELODYSPLASTIC SYNDROME; PILOT STUDY; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RASH; RELAPSE; SERUM SICKNESS; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UREMIA;

ADOLESCENT; ADULT; AGED; ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BONE MARROW DISEASES; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; RED-CELL APLASIA, PURE; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 56949093138     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.08.004     Document Type: Article

References (43)

1. Sugawara T., Endo K., Shishido T., Sato A., Kameoka J., Fukuhara O., et al. T cell-mediated inhibition of erythropoiesis in myelodysplastic syndromes. Am J Hematol 41 (1992) 304-305
2. Manz C.Y., Dietrich P.Y., Schnuriger V., Nissen C., and Wodnar-Filipowicz A. T-cell receptor beta chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia. Blood Cells Mol Dis 23 (1997) 110-122
3. Melenhorst J.J., Fibbe W.E., Struyk L., van der Elsen P.J., Willemze R., and Landegent J.E. Analysis of T-cell clonality in bone marrow of patients with acquired aplastic anaemia. Br J Haematol 96 (1997) 85-91
4. Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., and Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102 (1998) 1314-1322
5. Kochenderfer J.N., Kobayashi S., Wieder E.D., Su C., and Molldrem J.J. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100 (2002) 3639-3645
6. Kaulen D.R., Golovanova T.A., Pyatikhina D.P., and Khorobrikh V.V. Inhibition of haemopoietic stem cells by syngeneic lymphocytes treated with antilymphocyte serum. Folia Biol (Praha) 21 (1975) 95-102
7. Jansen J., Veenhof W.F., and Goselink H.M. Anti-thymocyte globulin effective in the treatment of aplastic anemia does not stimulate granulocyte precursor cells. Exp Hematol 9 (1981) 1028-1034
8. Doney K., Martin P., Storb R., Whitehead J., Smith A., Hansen J.A., et al. A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia. Exp Hematol 13 (1985) 520-524
9. Huang A.T., Mold N.G., and Zhang S.F. Antithymocyte globulin stimulates human hematopoietic progenitor cells. Proc Natl Acad Sci USA 84 (1987) 5942-5946
10. Tong J., Bacigalupo A., Piaggio G., Figari O., and Marmont A. Effect of antilymphocyte globulin (ALG) on bone marrow T/non-T cells from aplastic anaemia patients and normal controls. Br J Haematol 73 (1989) 546-550
11. Franzke A., Geffers R., Hunger J.K., Pfortner S., Piao W., Ivanyi P., et al. Identification of novel regulators in T-cell differentiation of aplastic anemia patients. BMC Genom 7 (2006) 263
12. Gluckman E., Esperou-Bourdeau H., Baruchel A., Boogaerts M., Briere J., Donadio D., et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood 79 (1992) 2540-2546
13. Marsh J., Schrezenmeier H., Marin P., Ilhan O., Ljungman P., McCann S., et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 93 (1999) 2191-2195
14. Bacigalupo A., Bruno B., Saracco P., Di Bona E., Locasciulli A., Locatelli F., et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 95 (2000) 1931-1934
15. Kojima S., Hibi S., Kosaka Y., Yamamoto M., Tsuchida M., Mugishima H., et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 96 (2000) 2049-2054
16. Frickhofen N., Heimpel H., Kaltwasser J.P., and Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101 (2003) 1236-1242
17. Scheinberg P., Nunez O., Wu C., and Young N.S. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 133 (2006) 606-611
18. Teramura M., Kimura A., Iwase S., Yonemura Y., Nakao S., Urabe A., et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults; a multicenter randomized study in Japan. Blood 110 (2007) 1756-1761
19. Champlin R.E., Ho W.G., Feig S.A., Winston D.J., Lenarsky C., and Gale R.P. Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Blood 66 (1985) 184-188
20. Greenwood J., Gorman S.D., Routledge E.G., Lloyd I.S., and Waldmann H. Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis. Ther Immunol 1 (1994) 247-255
21. Williams R.J., Clarke E., Blair A., Evely R., Hale G., Waldmann H., et al. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G. Cytotherapy 2 (2000) 5-14
22. Nuckel H., Frey U.H., Roth A., Duhrsen U., and Siffert W. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 514 (2005) 217-224
23. Willis F., Marsh J.C., Bevan D.H., Killick S.B., Lucas G., Griffiths R., et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 114 (2001) 891-898
24. Ru X., and Liebman H.A. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 123 (2003) 278-281
25. Au W.Y., Lam C.C., Chim C.S., Pang A.W., and Kwong Y.L. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res 29 (2005) 1213-1215
26. Schutzinger C., Gaiger A., Thalhammer R., Vesely M., Fritsche-Polanz R., Schwarzinger I., et al. Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia 19 (2005) 2005-2008
27. Lee J.H., Lee J.H., Choi S.J., and Lee K.H. Alemtuzumab treatment for aplastic anemia and low risk myelodysplastic syndrome: preliminary results. Proc Kor Soc Hematol 42 (2007) 88
28. Frickhofen N., and Rosenfeld S.J. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol 37 (2000) 56-68
29. Young N.S., and Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 336 (1997) 1365-1372
30. Dufour C., Corcione A., Svahn J., Haupt R., Battilana N., and Pistoia V. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol 115 (2001) 1023-1031
31. Watanabe T., Masuyama J., Sohma Y., Inazawa H., Horie K., Kojima K., et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 120 (2006) 247-259
32. Shah A., Lowenstein H., Chant A., and Khan A. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro. Transpl Int 19 (2006) 749-758
33. Rowan W.C., Hale G., Tite J.P., and Brett S.J. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 7 (1995) 69-77
34. Gilleece M.H., and Dexter T.M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82 (1993) 807-812
35. Wing M.G., Moreau T., Greenwood J., Smith R.M., Hale G., Isaacs J., et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98 (1996) 2819-2826
36. Rowan W., Tite J., Topley P., and Brett S.J. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95 (1998) 427-436
37. Rezvany M.R., Tehrani M.J., Karlsson C., Lundin J., Rabbani H., Osterborg A., et al. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 135 (2006) 475-485
38. Kirsch B.M., Haidinger M., Zeyda M., Bohmig G.A., Tombinsky J., Muhlbacher F., et al. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol 16 (2006) 254-257
39. Rosenfeld S., Follmann D., Nunez O., and Young N.S. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 289 (2003) 1130-1135
40. Kim I., Yoon S.S., Park S., Kim B.K., and Kim N.K. The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea. J Kor Med Sci 18 (2003) 365-371
41. Ahn M.J., Choi J.H., Lee Y.Y., Choi I.Y., Kim I.S., Yoon S.S., et al. Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial. Int J Hematol 78 (2003) 133-138
42. Tichelli A., Gratwohl A., Wuersch A., Nissen C., and Speck B. Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 68 (1988) 139-140
43. Young N., Griffith P., Brittain E., Elfenbein G., Gardner F., Huang A., et al. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood 72 (1988) 1861-1869